81 related articles for article (PubMed ID: 20538723)
1. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats.
Kagan L; Dreifinger T; Mager DE; Hoffman A
Drug Metab Dispos; 2010 Sep; 38(9):1560-6. PubMed ID: 20538723
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
Pathak SM; Udupa N
Biopharm Drug Dispos; 2010 Mar; 31(2-3):202-14. PubMed ID: 20238375
[TBL] [Abstract][Full Text] [Related]
4. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
5. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.
Shirasaka Y; Kuraoka E; Spahn-Langguth H; Nakanishi T; Langguth P; Tamai I
J Pharmacol Exp Ther; 2010 Jan; 332(1):181-9. PubMed ID: 19779132
[TBL] [Abstract][Full Text] [Related]
6. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
7. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
[TBL] [Abstract][Full Text] [Related]
8. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway.
Shingaki T; Hidalgo IJ; Furubayashi T; Sakane T; Katsumi H; Yamamoto A; Yamashita S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):248-55. PubMed ID: 21317541
[TBL] [Abstract][Full Text] [Related]
9. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
10. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
11. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
13. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
Gramatté T; Oertel R
Clin Pharmacol Ther; 1999 Sep; 66(3):239-45. PubMed ID: 10511059
[TBL] [Abstract][Full Text] [Related]
14. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
15. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
16. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
17. In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats.
Catalán-Latorre A; Nácher A; Merino V; Jiménez-Torres NV; Merino-Sanjuán M
Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):245-52. PubMed ID: 21535410
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the intestinal digoxin absorption and exsorption by quinidine.
Su SF; Huang JD
Drug Metab Dispos; 1996 Feb; 24(2):142-7. PubMed ID: 8742224
[TBL] [Abstract][Full Text] [Related]
19. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
20. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
